Host-cell reactivation of cisplatin-damaged pRSVcat in a human lymphoid cell line
- 1 October 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 11 (10) , 1761-1764
- https://doi.org/10.1093/carcin/11.10.1761
Abstract
A method has been developed for studying host-cell reactivation of cisplatin-damaged plasmid DNA in human T lymphocytes. Parameters of electroporation were established for transfection of the shuttle vector pRSVcat into H9 cells, and a rapid single-vial assay was used for measurement of chloramphenicol acetyltransferase (CAT) activity in extracts of transfected cells. pRSVcat was modified with cisplatin to defined levels ranging from 5 to 40 platinum molecules per plasmid, and then transfected into H9 cells. Graded reductions in CAT activity were observed with increasing levels of platination of the plasmid. At 40 platinum molecules per plasmid, CAT activity was reduced to levels of the negative controls. The efficiency of electroporation-mediated transfer of plasmid into H9 cells was not reduced by high levels of cisplatin modification. The level of modification effecting a 63% reduction in CAT gene expression (the B0 was found to be 17 cisplatin molecules per plasmid. This assay system offers a rapid and sensitive method for assessing the capability of human lymphoid cells to reactivate cisplatindamaged plasmid DNA.This publication has 13 references indexed in Scilit:
- Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor.Proceedings of the National Academy of Sciences, 1989
- MAC TECHNIQUE (MORPHOLOGY ANTIBODY CHROMOSOMES) IN PHENOTYPIC IDENTIFICATION OF PROLIFERATING NK-CELLS AND T-CELLS IN INTERLEUKIN-2-STIMULATED LYMPHOCYTE-CULTURES1989
- Electroporation: application to human lympboid cell lines for stable introduction of a transactivator gene of human T-cell leukemia virus type INucleic Acids Research, 1989
- The measurement of cisplatin-DNA adduct levels in testicular cancer patientsCarcinogenesis: Integrative Cancer Research, 1988
- FORMATION OF BLOCKING LESIONS AT IDENTICAL DNA-SEQUENCES BY THE NITROSOUREA AND PLATINUM CLASSES OF ANTICANCER DRUGS1987
- Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.Proceedings of the National Academy of Sciences, 1987
- Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells.Molecular and Cellular Biology, 1986
- Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.Journal of Clinical Investigation, 1986
- Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II).Proceedings of the National Academy of Sciences, 1985
- The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.Proceedings of the National Academy of Sciences, 1982